26. COST-UTILITY ANALYSES OF GLOFITAMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY IN ITALY
26. COST-UTILITY ANALYSES OF GLOFITAMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSEDREFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY IN ITALY